Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Of the Cardiac-specific Deaths, Deaths from Heart Attack and Sudden Heart Rhythm Disturbances declined steeply, no decline in deaths from Heart Failure in a 20,000 PCI patients Study @ Mayo Clinic

Reporter: Aviva Lev-Ari, PhD, RN

• Original Article

Traci Klein (@traciklein) published a blog post · February 6th, 2014

Surprising Trends in Cause of Long-Term Death for Heart Patients

ROCHESTER, Minn. — Feb. 6, 2014 — More people who have known coronary heart disease die from other causes — such as cancer, and lung and neurological diseases — than heart disease, compared with 20 years ago, according to a Mayo Clinic study published online Feb. 10 in Circulation, an American Heart Association journal.

VIEW VIDEO – Dr. Rajiv Gulati, MD, PhD

http://www.youtube.com/watch?v=f2-4t_sAN9A

The researchers evaluated the trends in cause-specific, long-term mortality from 1991 to 2008 in patients at Mayo Clinic in Rochester who underwent percutaneous coronary intervention (PCI), a procedure used to open clogged heart arteries. They broke the study population into three eras: 1991 to 1996, 1997 to 2002, and 2003 to 2008. Cardiac deaths predominated in the first era and were about equal with non-cardiac deaths in the middle era. In the final era — the modern-era (2003 to 2008) — non-cardiac deaths dominated.

Approximately 20,000 PCI patients were studied. Of those, nearly 7,000 patients died within the study time frame. Among that group, only 37 percent of deaths in the modern-era (2003-2008) were cardiac-related.

“We found that patients with established heart disease undergoing angioplasty and stenting in the modern era have about a 1 in 3 chance of dying from their heart disease, and a 2 in 3 chance of dying from non-cardiac diseases in the long term,” says Rajiv Gulati, M.D., Ph.D., senior author and Mayo Clinic interventional cardiologist.

The results surprised the authors, Dr. Gulati says. First, patients undergoing angioplasty in the modern era have gotten older, with more complex coronary disease and more risk factors compared with years ago. So, the authors were expecting their cardiac death rates to have increased. “In addition, in randomized clinical trials of PCI, deaths from cardiac disease still predominate,” he says. The authors believe the sharp decline in long-term cardiac deaths in these patients may result from improved cardiac therapies. For example, more patients today with established heart disease take medications to lower cholesterol, prevent heart failure, and decrease blood pressure, and technologies used in catheterization laboratories — where PCI is performed — have improved, Dr. Gulati says.

Of the cardiac-specific deaths, deaths from heart attack and sudden heart rhythm disturbancesdeclined steeply, but there was no decline in deaths from heart failure.

“These results show that we have an opportunity to focus on the non-cardiac diseases in these patients — to treat the patient holistically,” Dr. Gulati says. “But it also gives us the opportunity to identify and target those patients who are at risk of dying from heart disease.”

About Mayo Clinic
Recognizing 150 years of serving humanity in 2014, Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit150years.mayoclinic.org, http://www.mayoclinic.org/ and newsnetwork.mayoclinic.org.

---

MEDIA CONTACT: Traci Klein, Mayo Clinic Public Affairs, 507-284-5005,newsbureau@mayo.edu

SOURCE

http://newsnetwork.mayoclinic.org/discussion/mayo-study-finds-surprising-trends-in-cause-of-long-term-death-after-percutaneous-coronary-intervent

Other related articles published in this Open Access Online Scientific Journal include the following:

AHA, ACC Change in requirement for surgical support:  Class IIb -> Class IIa Level of Evidence A: Supports Nonemergent PCI without Surgical Backup (Change of class IIb, level of Evidence B).

Larry H Bernstein, MD, FCAP and Justin D Pearlman, MD, PhD, FACC

Coronary Artery Disease – Medical Devices Solutions: From First-In-Man Stent Implantation, via Medical Ethical Dilemmas to Drug Eluting Stents |Comments »

Aviva Lev-Ari, PhD, RN

Absorb™ Bioresorbable Vascular Scaffold: An International Launch by Abbott Laboratories |Comments »

Aviva Lev-Ari, PhD, RN

To Stent or Not? A Critical Decision

Aviva Lev-Ari, PhD, RN

New Drug-Eluting Stent Works Well in STEMI: Meta-analysis makes the Case

Aviva Lev-Ari, PhD, RN

Drug Eluting Stents: On MIT’s Edelman Lab’s Contributions to Vascular Biology and its Pioneering Research on DES

Larry H Bernstein, MD, FACP and  Aviva Lev-Ari, PhD, RN

Stent Design and Thrombosis:  Bifurcation Intervention, Drug Eluting Stents (DES) and Biodegrable Stents

Aviva Lev-Ari, PhD, RN